Low-dose growth hormone-releasing factor may enhance folliculogenesis in regularly menstruating women: a preliminary study

Duffy, Daniel M.; Lindheim, Steven R.; Vijod, Marcela A.; Chang, Luke L. Y.; Nakamura, Robert M.; Løbo, Rogerio A.

doi:10.1016/s0015-0282(16)57477-9

Cited by 5 publications

(3 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…1986; Mason et al, 1990;Moretti et al, 1990;Bagnato et al, 1991;Adashi and Rohan, 1992;Apa et al, 1995;Doldi et al, 1996;Hugues et al, 1996). Although previous studies with exogenous GH obtained conflicting results (Homburg et al, 1990;Bergh et al, 1994;Hughes et al, 1994), studies with GRF suggested that stimulation of GH production by this hormone was associated with slight improvements in the number of recruited follicles and retrieved oocytes (Hugues et al, 1991;Duffy et al, 1995;Busacca et al, 1996a, b).…”

Section: Discussionmentioning

confidence: 99%

“…In a pilot study in IVF patients, administration of GRF was associated with a significant improvement in the ovarian response to HMG (in terms of plasma oestradiol concentrations), and slight increases in the number of recruited follicles and retrieved oocytes (Hugues et al, 1991). More recently, a case study has reported induction of ovulation after GRF treatment in a woman who had previously failed to respond to gonadotrophin stimulation (Busacca et al, 1996a) and controlled trials have suggested that GRF treatment can induce folliculogenesis and reduce the dose of gonadotrophin required for follicular growth (Duffy et al, 1995;Busacca et al, 1996b). In view of these findings, a controlled, multicentre trial was carried out to evaluate the efficacy and tolerability of GRF treatment in poorly responsive patients undergoing ovulation induction with FSH (Metrodin ® ; Ares-Serono, Geneva, Switzerland) and a gonadotrophin-releasing hormone agonist (GnRHa) prior to IVF.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Does growth hormone-releasing factor assist follicular development in poor responder patients undergoing ovarian stimulation for in-vitro fertilization?

Howles¹,

Loumaye²,

Germond³

et al. 1999

Human Reproduction

View full text Add to dashboard Cite

Treatment with growth hormone-releasing factor (GRF) has been reported to improve the ovarian response to gonadotrophins in women who respond poorly to ovarian stimulation during in-vitro fertilization (IVF). The efficacy and tolerability of GRF were studied in a randomized, double-blind, placebo-controlled trial involving 196 patients. Following down-regulation with a gonadotrophin-releasing hormone agonist (GnRHa), patients were randomized to receive GRF (500 microg twice daily; n = 96) or placebo (n = 100) in addition to follicle stimulating hormone (FSH); treatment was continued until human chorionic gonadotrophin was given, or for a maximum of 14 days. GRF had no significant effect on the mean number of follicles with a diameter of >/=16 mm (GRF: 3.26 +/- 2.29; placebo: 3.27 +/- 2.30; P = 0.95), the number of FSH ampoules required to achieve ovarian stimulation (GRF: 55.2 +/- 16. 4; placebo: 54.9 +/- 17.2; P = 0.50), or on secondary measures of ovarian response and treatment outcome. There were, however, significant increases in circulating growth hormone (GH) and insulin-like growth factor (IGF)-1 concentrations. GRF was well tolerated. It is concluded that, despite producing significant increases in GH and IGF-1, concomitant treatment with GRF does not improve the ovarian response to FSH in poorly responsive women undergoing IVF.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Does growth hormone-releasing factor assist follicular development in poor responder patients undergoing ovarian stimulation for in-vitro fertilization?

Howles¹,

Loumaye²,

Germond³

et al. 1999

Human Reproduction

View full text Add to dashboard Cite

show abstract

“…For at least half a decade, arguments for and against cotreatment of women with gonadotropin-nonresponsive ovulation failure have occupied center stage in discussions of adjunctive ovulation therapy. 16 Investigators utilizing growth hormone, [18][19][20][21] growth hormone-releasing hormone, 22,23 and a variety of newly synthesized growth hormone secretogogues have experienced mixed results in their ability to enhance traditional gonadotropin therapies. Delineation of the actual (as opposed to theoretical) mechanisms of growth hormone action on the ovary remain to be elucidated.…”

Section: Adjunctive Therapies With Existing Agentsmentioning

confidence: 99%

The Evolution of New Agents for Ovulation Induction

Gast

1996

Semin Reprod Med

View full text Add to dashboard Cite

The field of clinical ovulation-induction therapy has remained relatively static for over 30 years. This field promises to benefit from advances in our understanding of the biology of ovulation, and from exciting new work in the areas of molecular and cellular biology and in the biochemistry of steroids, gonadotropins, and their receptors. New therapies with recombinant gonadotropins and their analogues show promise for the near future. Advances in our ability to stimulate and suppress the reproductive axis through central mechanisms also show some promise. In the long term, our understanding of the mechanisms involved in folliculogenesis and oocyte maturation may be combined with an enhanced ability to dissect these processes that lead to disordered ovulation. Our improved understanding of the implantation process may well lead to an ability to create nearly universal nidation in women who are undergoing ART or who have implantation disorders. This article discusses some of the many new opportunities in the clinical and basic science of ovulation induction. New technologies, such as those available through the Human Genome Project, and the use of genetic manipulation of animal models will stimulate additional new avenues of research.

show abstract

Therapeutic management in women with a diminished ovarian reserve: a systematic review and meta-analysis of randomized controlled trials

Conforti,

Carbone,

Di Girolamo

et al. 2024

Fertility and Sterility

View full text Add to dashboard Cite

Low-dose growth hormone-releasing factor may enhance folliculogenesis in regularly menstruating women: a preliminary study

Cited by 5 publications

References 26 publications

Does growth hormone-releasing factor assist follicular development in poor responder patients undergoing ovarian stimulation for in-vitro fertilization?

Does growth hormone-releasing factor assist follicular development in poor responder patients undergoing ovarian stimulation for in-vitro fertilization?

The Evolution of New Agents for Ovulation Induction

Therapeutic management in women with a diminished ovarian reserve: a systematic review and meta-analysis of randomized controlled trials

Contact Info

Product

Resources

About